Search

  • HOME
  • Search
Editorial
Allergy
Clinical considerations and practical issues of allergic diseases in COVID-19 era
Sungsu Jung
Clin Exp Pediatr. 2022;65(12):587-588.   Published online November 29, 2022
The risk of sudden acute respiratory syndrome coronavirus 2 infection and severe coronavirus disease 2019 (COVID-19) outcomes is not elevated in patients with the type 2 phenotype and well-controlled asthma. Inhaled corticosteroids, intranasal corticosteroids, and topical steroids can be safely used in COVID-19 patients. Biologics can be safely used by patients with allergic diseases without concern about antibody responses.
  • PubMed Central
  • PubMed
  • Scopus
  • Directory of Open Access Journals (DOAJ)